Published in Cancer Weekly, December 8th, 2009
The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.
"We are very pleased to initiate the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.